|
AstraZeneca PLC on Monday said Enhertu reduced the risk of disease progression in a form of breast cancer. The Cambridge, England-based pharmaceutical company said Enhertu plus pertuzumab reduced the risk of disease progression in HER2-positive metastatic breast cancer by 44%, when compared to taxane, trastuzumab & pertuzumab or THP. This was as a first-line treatment for patients with this form of cancer. Enhertu is an antibody drug conjugate that AstraZeneca develops jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd. Ken Takeshita, global head, research & development at Daiichi, said: ‘Enhertu continues to transform the treatment of metastatic breast cancer with the first new data in more than a decade to demonstrate improved outcomes for a broad population of patients with HER2-positive disease compared to THP in the first-line setting. ‘Destiny-Breast09 shows that initiating treatment with Enhertu in combination with pertuzumab at the time of metastatic diagnosis can delay disease progression.’ Susan Galbraith, executive vice president, Oncology Haematology R&D at AstraZeneca, said: ‘Bringing Enhertu earlier in the treatment of HER2-positive metastatic breast cancer may represent an important advancement for patients. ‘The Destiny-Breast09 trial showed the combination of Enhertu and pertuzumab in the first-line setting substantially increased the amount of time before a patient’s cancer progressed compared to standard of care and nearly doubled the number of patients showing no signs of disease on imaging. ‘Establishing a strong therapeutic response as soon as metastatic disease is diagnosed is critical given that about one in three patients do not receive further treatment after progressing in the first-line setting.’ AstraZeneca shares were 1.4% lower at 10,570.00 pence each on Monday afternoon in London, while Daiichi shares had closed 0.7% lower at JP¥3,816.00 each in Tokyo. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
